We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Tilray, Inc. (TLRY) Stock Sinks As Market Gains: What You Should Know
Read MoreHide Full Article
Tilray, Inc. (TLRY - Free Report) closed at $79.07 in the latest trading session, marking a -0.16% move from the prior day. This change lagged the S&P 500's daily gain of 0.64%. Meanwhile, the Dow gained 0.7%, and the Nasdaq, a tech-heavy index, added 0.91%.
Coming into today, shares of the company had gained 7.08% in the past month. In that same time, the Medical sector gained 2.07%, while the S&P 500 gained 4.16%.
Investors will be hoping for strength from TLRY as it approaches its next earnings release, which is expected to be March 18, 2019.
Investors might also notice recent changes to analyst estimates for TLRY. These recent revisions tend to reflect the evolving nature of short-term business trends. As such, positive estimate revisions reflect analyst optimism about the company's business and profitability.
Research indicates that these estimate revisions are directly correlated with near-term share price momentum. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.
The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate remained stagnant. TLRY currently has a Zacks Rank of #3 (Hold).
The Medical - Drugs industry is part of the Medical sector. This group has a Zacks Industry Rank of 73, putting it in the top 29% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
You can find more information on all of these metrics, and much more, on Zacks.com.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Tilray, Inc. (TLRY) Stock Sinks As Market Gains: What You Should Know
Tilray, Inc. (TLRY - Free Report) closed at $79.07 in the latest trading session, marking a -0.16% move from the prior day. This change lagged the S&P 500's daily gain of 0.64%. Meanwhile, the Dow gained 0.7%, and the Nasdaq, a tech-heavy index, added 0.91%.
Coming into today, shares of the company had gained 7.08% in the past month. In that same time, the Medical sector gained 2.07%, while the S&P 500 gained 4.16%.
Investors will be hoping for strength from TLRY as it approaches its next earnings release, which is expected to be March 18, 2019.
Investors might also notice recent changes to analyst estimates for TLRY. These recent revisions tend to reflect the evolving nature of short-term business trends. As such, positive estimate revisions reflect analyst optimism about the company's business and profitability.
Research indicates that these estimate revisions are directly correlated with near-term share price momentum. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.
The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate remained stagnant. TLRY currently has a Zacks Rank of #3 (Hold).
The Medical - Drugs industry is part of the Medical sector. This group has a Zacks Industry Rank of 73, putting it in the top 29% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
You can find more information on all of these metrics, and much more, on Zacks.com.